|
|
|
|
| FDA Recalls Contaminated Cefazolin
|
|
Cefazolin for Injection USP is under a recall by the FDA and manufacturer Hanford Pharmaceuticals due to microbial contamination of the commonly used pre-op antibiotic.
Four lots — nearly 380,000 1g/10ml vials — are subject to the recall because certain lots of the active ingredient used to manufacture the product were found to be contaminated with Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes or Micrococcus luteus, which may pose serious or life-threatening risks to some patients.
Hospitals, clinics and other providers should immediately stop using the affected lots, which were distributed by Sandoz, Inc., of Broomfield, Colo., under the lot numbers C4650 and C4537 and by Watson Pharmaceuticals, Inc., of Corona, Calif., under the lot numbers C4689 and C4665.
Hanford Pharmaceuticals says it hasn't yet received any confirmed reports of adverse events or complaints related to the recalled lots. You should report any product-related reactions or problems to the FDA MedWatch Program, either through an online form, calling (800) FDA-1088 or faxing (800) FDA-0178.
|
|
 |
^ Back to Top |
|
|
|
|
| The "Five Most Dangerous Trends" Hospitals Face
|
|
Cefazolin for Injection USP is under a recall by the FDA and manufacturer Hanford Pharmaceuticals due to microbial contamination of the commonly used pre-op antibiotic.
Four lots — nearly 380,000 1g/10ml vials — are subject to the recall because certain lots of the active ingredient used to manufacture the product were found to be contaminated with Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes or Micrococcus luteus, which may pose serious or life-threatening risks to some patients.
Hospitals, clinics and other providers should immediately stop using the affected lots, which were distributed by Sandoz, Inc., of Broomfield, Colo., under the lot numbers C4650 and C4537 and by Watson Pharmaceuticals, Inc., of Corona, Calif., under the lot numbers C4689 and C4665.
Hanford Pharmaceuticals says it hasn't yet received any confirmed reports of adverse events or complaints related to the recalled lots. You should report any product-related reactions or problems to the FDA MedWatch Program, either through an online form, calling (800) FDA-1088 or faxing (800) FDA-0178.
|
|
|
^ Back to Top |
|
|
|
|
| Plastic Surgery Patients More Likely to Take Herbal Supplements
|
|
Cefazolin for Injection USP is under a recall by the FDA and manufacturer Hanford Pharmaceuticals due to microbial contamination of the commonly used pre-op antibiotic.
Four lots — nearly 380,000 1g/10ml vials — are subject to the recall because certain lots of the active ingredient used to manufacture the product were found to be contaminated with Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes or Micrococcus luteus, which may pose serious or life-threatening risks to some patients.
Hospitals, clinics and other providers should immediately stop using the affected lots, which were distributed by Sandoz, Inc., of Broomfield, Colo., under the lot numbers C4650 and C4537 and by Watson Pharmaceuticals, Inc., of Corona, Calif., under the lot numbers C4689 and C4665.
Hanford Pharmaceuticals says it hasn't yet received any confirmed reports of adverse events or complaints related to the recalled lots. You should report any product-related reactions or problems to the FDA MedWatch Program, either through an online form, calling (800) FDA-1088 or faxing (800) FDA-0178.
|
|
|
^ Back to Top |
|
|
|
|
| News and Notes
|
|
TENET HEALTHCARE, the Dallas-based hospital corporation, has agreed to pay 22 states and the federal government $820,000 in a settlement over concerns that some of its hospitals improperly billed Medicare and other insurers for outpatient lab services. The company itself alerted the U.S. Department of Justice in 1997, turning over evidence that hospitals had submitted claims for lab tests of questionable medical necessity and "unbundled" claims, which illegally reaped a higher reimbursement by billing related tests separately instead of grouping them into panels.
|
|
|
^ Back to Top |
|
|
|
|
|
|
